Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | GSK3B | P49841 | 4/20 | 0.77 |
| ▸ | GSK3A | P49840 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.77 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16157040 | 0.94 | EGFR (0.80) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL16157092 | 0.89 | EGFR (0.88) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL928258 | 0.89 | EGFR (1.00) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL17480620 | 0.88 | EGFR (0.80) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL16157177 | 0.87 | GSK3B (1.00) | SMN1; SMN2GSK3BGSK3AHTTALDH1A1 | |
| SCHEMBL16157074 | 0.86 | EGFR (0.94) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL16157175 | 0.86 | GSK3B (0.71) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL16157174 | 0.86 | HTT (0.73) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL16157032 | 0.86 | GSK3B (0.81) | EGFRSMN1; SMN2GSK3BGSK3AHTT | |
| SCHEMBL16157117 | 0.85 | EGFR (0.80) | EGFRSMN1; SMN2GSK3BGSK3AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | MASSACHUSETTS GENERAL HOSPITAL | 2020-05-07 | — | — | US | disclosed |
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| WO-2014165090-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | GOT2, G6PD, FNTB | EGFR 4472/4885SMN1; SMN2 4593/4885GSK3B 2519/4885 |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | EGFR 4472/4885SMN1; SMN2 4593/4885GSK3B 2519/4885 |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | EGFR 4472/4885SMN1; SMN2 4593/4885GSK3B 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.